Education
About Us
Working with TipRanks
Follow Us
Fresenius SE & Co (FSNUY)
OTHER OTC:FSNUY
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.19Last Year’s EPS
0.19Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 3.65%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, strategic restructuring, and resumed dividend payments, indicating overall progress. However, challenges in China, the end of energy relief payments, and competitive pressures in Biopharma create headwinds.Company Guidance
During the call, Fresenius provided a comprehensive outlook for 2025, emphasizing continued momentum in financial and operational performance. The guidance for the fiscal year 2025 includes organic revenue growth of 4% to 6% and EBIT growth of 3% to 7%, both at constant currency. The company highlighted significant achievements in 2024, including surpassing €470 million in structural cost improvements and achieving high single-digit organic revenue growth, with EBIT expanding even faster in double digits. Key growth drivers were the MedTech, Nutrition, and Biopharma segments, with Biopharma particularly standing out with 76% year-over-year growth. The company also noted Helios' consistent revenue performance and a substantial improvement in EPS, moving from a 13% decline in 2022 to 14% growth in 2024. The guidance reflects a confident outlook, with a focus on executing its "Rejuvenate" strategy and achieving further operational efficiencies and market expansion.Strong Financial Performance in 2024
Fresenius achieved high single-digit organic revenue growth, with EBIT growing even faster in double digits. Key growth drivers included MedTech, Nutrition, and Biopharma, with Biopharma showing 76% year-over-year growth.
Significant Margin and Cash Flow Improvement
The company improved its EBIT margins by 180 basis points over the past two years and achieved a strong EPS growth of 14% in 2024, compared to a 13% decline in 2022. Operating cash flow neared €1 billion in the fourth quarter.
Successful Portfolio Restructuring
Fresenius successfully concluded several strategic measures, including divesting non-core assets, deconsolidating Fresenius Medical Care, and exiting Vamed, resulting in a simpler and more focused company.
Resumption of Dividend Payments
Fresenius announced a proposed dividend of €1 per share for 2024, reflecting financial strength and a commitment to shareholder value.
---
FSNUY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FSNUY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $9.60 | $10.23 | +6.56% |
| Nov 06, 2024 | $9.22 | $9.32 | +1.08% |
| Jul 31, 2024 | $8.62 | $8.98 | +4.18% |
| May 08, 2024 | $7.58 | $7.65 | +0.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fresenius SE & Co (FSNUY) report earnings?
Fresenius SE & Co (FSNUY) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is Fresenius SE & Co (FSNUY) earnings time?
Fresenius SE & Co (FSNUY) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FSNUY EPS forecast?
FSNUY EPS forecast for the fiscal quarter 2024 (Q4) is 0.19.
---